De Leeuw, Elisabeth
Van Damme, Karel F. A.
Declercq, Jozefien
Bosteels, Cedric
Maes, Bastiaan
Tavernier, Simon J.
Detalle, Laurent
Smart, Trevor
Glatt, Sophie
Debeuf, Nincy
Deckers, Julie
Lameire, Sahine
Vandecasteele, Stefaan J.
De Neve, Nikolaas
Demedts, Ingel K.
Govaerts, Elke
Knoop, Christiane
Vanhove, Karolien
Moutschen, Michel
Terryn, Wim
Depuydt, Pieter
Van Braeckel, Eva
Haerynck, Filomeen
Hendrickx, Tine C. J.
Parrein, Vanessa
Lalla, Marianna
Brittain, Claire
Lambrecht, Bart N.
Clinical trials referenced in this document:
Documents that mention this clinical trial
Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial
https://doi.org/10.1186/s12931-022-02126-2
Funding for this research was provided by:
UCB Pharma
Article History
Received: 29 April 2022
Accepted: 1 August 2022
First Online: 9 August 2022
Declarations
:
: The trial was approved by the Ethical Committee of Ghent University Hospital and conducted in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki. Every patient or their legal representative provided informed consent before participation.
: Not applicable.
: CeB, EDL, JoD, BM, KVD have received an FWO PhD Fellowship. ND, JuD, SJT have received an FWO Postdoctoral Grant. ClB, LD, SG, ML, TS are employed by UCB. VP is employed by Sillar Clinical N.V. ClB, LD, ML, TS hold stock or stock options from UCB. LD holds stock or stock options from Sanofi. TS holds stock or stock options from Pfizer and Lilly. ClB, BNL, EVB have contributed or participated on a DSMB or Advisory Board. BNL has received a grant from Partner Therapeutics, Inc., has received consulting fees and payments from Sanofi and GSK and holds stock options from Argenx. EVB has received a grant from Ghent University, is principal investigator in a trial sponsored by Exevir Bio and has received consulting fees or payments from GSK, MDS and Gilead. ID, NDN, PD, EG, FH, TH, CK, SL, MM, WT, SV report no competing interests.